STRATA Skin Sciences (NASDAQ:SSKN) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of STRATA Skin Sciences (NASDAQ:SSKN) from a hold rating to a buy rating in a research report report published on Thursday morning, ValuEngine reports.

Several other equities research analysts also recently weighed in on the company. Northland Securities reaffirmed a buy rating and issued a $7.00 target price on shares of STRATA Skin Sciences in a research report on Tuesday, May 14th. HC Wainwright set a $5.00 target price on STRATA Skin Sciences and gave the stock a buy rating in a research report on Monday, July 8th. Finally, Zacks Investment Research downgraded STRATA Skin Sciences from a hold rating to a sell rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $4.92.

Shares of NASDAQ SSKN opened at $2.39 on Thursday. STRATA Skin Sciences has a 1-year low of $2.01 and a 1-year high of $3.88. The business has a 50-day moving average of $2.60 and a 200-day moving average of $2.71.

Several hedge funds and other institutional investors have recently modified their holdings of SSKN. Northern Trust Corp purchased a new stake in shares of STRATA Skin Sciences in the fourth quarter worth about $36,000. Virtu Financial LLC purchased a new stake in shares of STRATA Skin Sciences in the first quarter worth about $39,000. Creative Planning boosted its position in shares of STRATA Skin Sciences by 42.9% in the second quarter. Creative Planning now owns 50,000 shares of the medical device company’s stock worth $125,000 after buying an additional 15,000 shares during the period. Acadian Asset Management LLC boosted its holdings in STRATA Skin Sciences by 35.2% in the second quarter. Acadian Asset Management LLC now owns 52,715 shares of the medical device company’s stock valued at $131,000 after purchasing an additional 13,716 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in STRATA Skin Sciences by 33.5% in the second quarter. BlackRock Inc. now owns 82,972 shares of the medical device company’s stock valued at $207,000 after purchasing an additional 20,803 shares during the last quarter. 30.98% of the stock is owned by institutional investors.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

See Also: Understanding Analyst Recommendations

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.